Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4121413 | 0.88 | EPHX2 (0.54) | EPHX2 | |
| SCHEMBL4117347 | 0.86 | EPHX2 (0.81) | EPHX2 | |
| SCHEMBL4121410 | 0.85 | EPHX2 (0.64) | EPHX2 | |
| SCHEMBL4105218 | 0.85 | EPHX2 (0.66) | EPHX2HSD11B1 | |
| SCHEMBL1420825 | 0.80 | EPHX2 (0.68) | EPHX2 | |
| SCHEMBL4010832 | 0.78 | EPHX2 (0.68) | EPHX2HSD11B1 | |
| SCHEMBL6568592 | 0.78 | EPHX2 (0.54) | EPHX2HSD11B1 | |
| SCHEMBL4105151 | 0.78 | S1PR2 (0.57) | EPHX2HSD11B1 | |
| SCHEMBL4112779 | 0.77 | EPHX2 (1.00) | EPHX2 | |
| SCHEMBL4101944 | 0.77 | EPHX2 (0.53) | EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8466200-B2 | 2-adamantylurea derivatives as selective 11β-HSD1 inhibitors | MERCK PATENT GMBH (DE) | 2013-06-18 | — | — | US | disclosed |
| US-20120172396-A1 | 2-ADAMANTYLUREA DERIVATIVES AS SELECTIVE 11B-HSD1 INHIBITORS | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2012-07-05 | — | — | US | disclosed |
| US-8188288-B2 | 2-adamantylurea derivatives as selective 11beta-HSD1 inhibitors | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2012-05-29 | — | — | US | disclosed |
| US-20090227631-A1 | 2-ADAMANTYLUREA DERIVATIVES AS SELECTIVE 11BETA-HSD1 INHIBITORS | MERCK PATENT GESELLSCHAFT (DE) | 2009-09-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120172396-A1 | 2-ADAMANTYLUREA DERIVATIVES AS SELECTIVE 11B-HSD1 INHIBITORS | HSD11B1, HSD11B2, HSD17B1 | EPHX2 597/4885HSD11B1 1/4885 |
| US-20090227631-A1 | 2-ADAMANTYLUREA DERIVATIVES AS SELECTIVE 11BETA-HSD1 INHIBITORS | HSD11B1, HSD11B2, HSD17B1 | EPHX2 503/4885HSD11B1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.